Phase 3 Clinical Trials With Primary Completion Dates in January 2016

This is a list of Phase 3 trials with primary completion dates in January 2016 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.

The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.

SymbolCompanyPrimary Completion DatePhaseNCT IDTitle
ADMSAdamas Pharmaceuticals, Inc.2016-01-01Phase 3NCT02274766Efficacy and Safety Study of ADS-5102 in PD Patients With Levodopa-Induced Dyskinesia
CLVSClovis Oncology, Inc.2016-01-01Phase 3NCT01968213A Study of Rucaparib as Switch Maintenance Following Platinum-Based Chemotherapy in Patients With Platinum-Sensitive, High-Grade Serous or Endometrioid Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer
DERMDermira, Inc.2016-01-01Phase 3NCT02326272A Study to Evaluate the Efficacy and Safety of Two Dose Levels of Certolizumab Pegol (CZP) in Subjects With Plaque Psoriasis (PSO)
KERXKeryx Biopharmaceuticals, Inc.2016-01-01Phase 3NCT02268994KRX-0502 (Ferric Citrate) for the Treatment of IDA in Adult Subjects With NDD-CKD
MMSIMerit Medical Systems, Inc.2016-01-01Phase 3NCT02159898EndoMAXX EVT Compared to EndoMAXX
ONTXOnconova Therapeutics, Inc.2016-01-01Phase 3NCT01241500Randomized Study of ON 01910.Na in Refractory Myelodysplastic Syndrome Patients With Excess Blasts